Australia’s PBS Lists Nine New Drugs – Has Business Returned To Normal?
This article was originally published in PharmAsia News
Executive Summary
Australia’s Pharmaceutical Benefits Scheme adds drugs from AstraZeneca, GSK, BMS, Novartis, Pfizer and Roche as industry breathes a sigh of relief.
You may also be interested in...
Battle Over Deferred Drug Listings In Australia: Should Cost-Effective Drugs Always Be Funded?
A storm is brewing in the lead up to Australia's May 10 federal budget over the nation's Pharmaceutical Benefits Scheme, which acts as a single payer to subsidize drug prices and is administered by the government
Prima Shifts Focus To LAG-3 After Immutep Deal
The Australian immuno-therapeutics developer Prima BioMed has had a change of focus in recent months since buying Paris-based Immutep in late 2014. Prima’s lead product used to be its CVac cancer vaccine, but it has now shifted strategic priority to an LAG-3 immune checkpoint receptor that came with the acquisition.
Phylogica Surges On Early CPP Cancer Results
Phylogica is continuing its strong financial year, with the company’s shares surging after it announced that a pilot study for its cell-penetrating peptides (CPPs) showed these were able to kill drug-resistant breast cancer cells in vivo, when linked with the cancer drug Omomyc.